Pharming Group (PHGUF) to Release Quarterly Earnings on Thursday

Pharming Group (OTCMKTS:PHGUF) is expected to announce its results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of $0.0001 per share and revenue of $92.0570 million for the quarter.

Pharming Group (OTCMKTS:PHGUF) last announced its quarterly earnings results on Thursday, March 12th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $106.50 million during the quarter, compared to analyst estimates of $89.72 million. Pharming Group had a return on equity of 1.08% and a net margin of 0.71%.

Pharming Group Stock Down 6.6%

Shares of OTCMKTS PHGUF opened at $1.64 on Tuesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.03 and a current ratio of 2.59. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of 163.66 and a beta of 0.55. The stock has a 50 day moving average price of $1.60 and a 200 day moving average price of $1.65. Pharming Group has a 52-week low of $0.96 and a 52-week high of $2.17.

Pharming Group Company Profile

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.